LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

Search

Corcept Therapeutics Inc

Open

SectorHealthcare

76.72 3.3

Overview

Share price change

24h

Current

Min

73.35

Max

77.38

Key metrics

By Trading Economics

Income

-9.8M

21M

Sales

-25M

157M

P/E

Sector Avg

61.121

50.857

EPS

0.169

Profit margin

13.069

Employees

500

EBITDA

-22M

3.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+95.19% upside

Dividends

By Dow Jones

Next Earnings

28 lip 2025

Market Stats

By TradingEconomics

Market Cap

-194M

7.5B

Previous open

73.42

Previous close

76.72

News Sentiment

By Acuity

50%

50%

157 / 381 Ranking in Healthcare

Corcept Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 cze 2025, 19:24 UTC

Major Market Movers

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 cze 2025, 19:07 UTC

Major Market Movers

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

23 cze 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

FTC Resolves Antitrust Probe Into Omnicom-Interpublic Merger

23 cze 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 cze 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Fears About Israel-Iran Conflict Ease -- Market Talk

23 cze 2025, 23:39 UTC

Market Talk

Gold Falls After Trump Says Israel, Iran Agree to Cease-Fire -- Market Talk

23 cze 2025, 23:39 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23 cze 2025, 22:53 UTC

Market Talk

Global Equities Roundup: Market Talk

23 cze 2025, 21:42 UTC

Earnings

KB Home Cuts FY25 Outlook as 2Q Profit, Sales Fall -- Update

23 cze 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

23 cze 2025, 20:30 UTC

Market Talk

Canada Employment Data May Be Overstating Job Gains -- Market Talk

23 cze 2025, 20:24 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock Surges After Musk's Robo-Taxi Rollout. Where Shares Go From Here. -- Barrons.com

23 cze 2025, 20:16 UTC

Market Talk

U.S. Stocks Climb After Iran's Retaliation Seen As Measured -- Market Talk

23 cze 2025, 19:22 UTC

Market Talk

Oil Futures Sink As Iranian Retaliation Seen Weak -- Market Talk

23 cze 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

23 cze 2025, 18:49 UTC

Market Talk

Gold Ticks Higher in Cautious Trade -- Market Talk

23 cze 2025, 18:14 UTC

Market Talk

Global Energy Roundup: Market Talk

23 cze 2025, 18:14 UTC

Market Talk

Treasury Yields, Dollar Little Changed on Iran's Retaliation -- Market Talk

23 cze 2025, 17:59 UTC

Market Talk

Oil Futures Fall As Iran Fires Missiles At U.S. Bases in Qatar -- Market Talk

23 cze 2025, 17:25 UTC

Market Talk

Services Lift Mexico's Economic Activity in April -- Market Talk

23 cze 2025, 17:22 UTC

Market Talk

Weaker Oil Long-Term Looks to Keep a Lid on Grains -- Market Talk

23 cze 2025, 17:20 UTC

Market Talk

Mexican Inflation Seen Easing in Early June --Market Talk -- Market Talk

23 cze 2025, 16:27 UTC

Market Talk
Earnings

Commercial Metals Says Tariffs, Interest Rates Won't Drag on Earnings -- Market Talk

23 cze 2025, 16:23 UTC

Market Talk
Earnings

Commercial Metals Sees Resilient Demand, Eyes Growth as Economic Uncertainty Eases -- Market Talk

23 cze 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

23 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23 cze 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23 cze 2025, 15:50 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Didn't Disclose Financial Details

23 cze 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Impact on Credit Agricole's CET1 Ratio Expected to Be Limited

Peer Comparison

Price change

Corcept Therapeutics Inc Forecast

Price Target

By TipRanks

95.19% upside

12 Months Forecast

Average 139.33 USD  95.19%

High 145 USD

Low 131 USD

Based on 4 Wall Street analysts offering 12 month price targets forCorcept Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Sentiment

By Acuity

157 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.